Newron presents good results for pain blocker
Milan – The Italian CNS specialist Newron Pharmaceuticals SpA has announced positive results from a preclinical study on ralfinamide showing statistically significant analgesic benefits against spontaneous chronic pain in an experimental animal model of central pain. Ralfinamide is currently in phase IIb/III testing for neuropathic low back pain. The study, conducted by Professor Ze’ev Seltzer, Canada Senior Research Chair in Genetics of Pain, University of Toronto, was presented at the Sixth International Congress for the European Federation of IASP Chapters in Lisbon, Portugal. Researchers at Newron believe that ralfinamide mediates its analgesic effect through the inhibition of sodium channels in the cell.